Chemistry:AVN-101

From HandWiki
Short description: Chemical compound
AVN-101
AVN-101 Structure.svg
Identifiers
CAS Number
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H24N2
Molar mass304.437 g·mol−1
3D model (JSmol)

AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it was in phase II clinical trials for these indications.[2][3][4][needs update]

See also

References

  1. "Small Molecule 5-HT6R Ligands: A Comprehensive Insight into their Selectivity and Activity". Current Bioactive Compounds 9 (1): 64–100. 2013. doi:10.2174/1573407211309010007. ISSN 1573-4072. 
  2. 2.0 2.1 "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews. Drug Discovery 12 (9): 667–87. September 2013. doi:10.1038/nrd4075. PMID 23989795. 
  3. 3.0 3.1 "Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease". Journal of Medicinal Chemistry 57 (17): 7160–81. September 2014. doi:10.1021/jm5003952. PMID 24850589. 
  4. "AVN 101". AdisInsight. http://adisinsight.springer.com/drugs/800030006. 

External links